Table 4.
Experimental animal group | Reference | ASFV genotype II strain | Target | Sample size | Route | Doses | Duration (dpi) | Died due to disease | Euthanised due to disease | Case‐fatality rate |
---|---|---|---|---|---|---|---|---|---|---|
1 | Bernard et al. (2016) | Ambaton 02 | DP | 18 | ID | 104 HAD50 | 8 | 0 | 18 | 100 |
2 | Bernard et al. (2016) | Ambaton 02 | DP | 12 | ID | 102 HAD50 | 8 | 0 | 12 | 100 |
3 | Pietschmann et al. (2015) | Armenia 08 | WB | 6 | ON | 10 HAD50 | 36 | 6 | 0 | 100 |
4 | Pietschmann et al. (2015) | Armenia 08 | DP | 6 | ON | 100 HAD50 | 36 | 6 | 0 | 100 |
5 | Pietschmann et al. (2015) | Armenia 08 | DP | 6 | ON | 10 HAD50 | 36 | 6 | 0 | 100 |
6 | Pietschmann et al. (2015) | Armenia 08 | WB | 6 | ON | 100 HAD50 | 36 | 6 | 0 | 100 |
7 | Frederic et al. (2015) | Georgia 2007/1 | DP | 3 | IM | 103 TCID50 | 6 | 3 | 0 | 100 |
8 | Vlasova et al. (2015) | Kashino 04/13 | DP | 4 | IH | 50 HAD50 | 21 | 4 | 0 | 100 |
9 | Vlasova et al. (2015) | Kashino 04/13 | DP | 2 | DC | 503 HAD50 | 15 | 2 | 0 | 100 |
10 | Vlasova et al. (2015) | Boguchary 06/13 | DP | 4 | IH | 50 HAD50 | 11 | 4 | 0 | 100 |
11 | Vlasova et al. (2015) | Boguchary 06/13 | DP | 2 | IM | 503 HAD50 | 9 | 2 | 0 | 100 |
12 | Vlasova et al. (2015) | Boguchary 06/13 | DP | 2 | DC | 503 HAD50 | 9 | 2 | 0 | 100 |
13 | Vlasova et al. (2015) | Karamzino 06/13 | DP | 4 | IH | 50 HAD50 | 21 | 4 | 0 | 100 |
14 | Vlasova et al. (2015) | Karamzino 06/13 | DP | 2 | IM | 503 HAD50 | 11 | 2 | 0 | 100 |
15 | Vlasova et al. (2015) | Karamzino 06/13 | DP | 2 | DC | 503 HAD50 | 15 | 2 | 0 | 100 |
16 | Vlasova et al. (2015) | K 08/13 | DP | 4 | IM | 503 HAD50 | 11 | 4 | 0 | 100 |
17 | Vlasova et al. (2015) | Vyazma 08/13 | DP | 4 | IH | 50 HAD50 | 15 | 4 | 0 | 100 |
18 | Vlasova et al. (2015) | Vyazma 08/13 | DP | 2 | IM | 503 HAD50 | 8 | 2 | 0 | 100 |
19 | Vlasova et al. (2015) | Stavropol 01/08 | DP | 4 | IH | 50 HAD50/503 HAD50 | 9 | 4 | 0 | 100 |
20 | Guinat et al. (2014) | Georgia 2007/1 | DP | 16 | DC | 14 | 0 | 16 | 100 | |
21 | Guinat et al. (2014) | Georgia 2007/1 | DP | 16 | DC | 18 | 0 | 16 | 100 | |
22 | Guinat et al. (2014) | Georgia 2007/1 | DP | 16 | IM | 102 HAD50 | 12 | 1 | 15 | 100 |
23 | Karalyan et al. (2012) | Field strain from Armenia and Georgia | DP | 9 | IM | 7 | 9 | 100 | ||
24 | Gabriel et al. (2011) | Armenia/2008 | WB | 1 | IM | 103 HAD50 | 25 | 1 | 0 | 100 |
25 | Gabriel et al. (2011) | Armenia/2008 | WB | 3 | DC | NA | 25 | 3 | 0 | 100 |
26 | Gabriel et al. (2011) | Armenia/2008 | DP | 3 | DC | NA | 20 | 3 | 0 | 100 |
27 | Gabriel et al. (2011) | Armenia/2008 | WB | 6 | O | 25 | 6 | 0 | 100 | |
28 | Olesen et al., (2018) | POL/2015/Podlaskie/Lindholm | DP | 4 | DC | 7 | 0 | |||
29 | Olesen et al. (2018) | POL/2015/Podlaskie/Lindholm | DP | 4 | DC | NA | 21 | 0 | ||
30 | Olesen et al. (2018) | POL/2015/Podlaskie/Lindholm | DP | 4 | DC | NA | 21 | 0 | ||
31 | Olesen et al. (2018) | POL/2015/Podlaskie/Lindholm | DP | 4 | DC | 106 MTC | 21 | 0 | ||
32 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | DC | NA | 14 | 0 | 4 | 100 |
33 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 6 | DC | NA | 18 | 2 | 33.3 | |
34 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | IN | 104.5 TCID50 | 11 | 0 | 4 | 100 |
35 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | DC | NA | 12 | 0 | 4 | 100 |
36 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | DC | NA | 12 | 0 | 4 | 100 |
37 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | DC | NA | 14 | 1 | 2 | 75 |
38 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | IN | 104.5 TCID50 | 11 | 1 | 3 | 100 |
39 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | DC | NA | 16 | 2 | 50 | |
40 | Olesen et al. (2017) | POL14/WB7397#13 | DP | 4 | DC | NA | 14 | 0 | 4 | 100 |
41 | Karalyan et al. (2017) | NR | DP | 8 | IM | 104 HAD50 | 7 | 0 | 8 | 100 |
42 | Gallardo et al. (2017) | LT14/1490 | DP | 8 | IM | No pdf | 19 | 8 | 0 | 100 |
43 | Gallardo et al. (2017) | LT14/1490 | DP | 10 | DC | NA | 61 | 9 | 0 | 90 |
44 | Popescu et al. (2017) | Georgia 2007/1 | DP | 10 | IM | 104 HAD50 | 4 | 0 | 10 | 100 |
45 | Donnell et al. (2016) | Georgia 2007 | DP | 5 | IM | 103 HAD50 | 8 | 0 | 5 | 100 |
46 | Donnell et al. (2016) | Georgia 2007 | DP | 5 | IM | 103 HAD50 | 0 | 5 | 100 | |
47 | Donnell et al. (2016) | Georgia 2007 | DP | 5 | IM | 103 HAD50 | 9 | 0 | 5 | 100 |
48 | Donnell et al. (2017) | Georgia | DP | 5 | IM | 104 HAD50 | 7 | 0 | 5 | 100 |
49 | Donnell et al. (2017) | Georgia | DP | 5 | IM | 104 HAD50 | 7 | 0 | 5 | 100 |
50 | Burmakina et al. (2016) | Congo K‐49 | DP | 3 | IM | 103 HAU | 6 | 3 | 0 | 100 |
51 | Burmakina et al. (2016) | Congo K ‐49 | DP | 3 | IM | 103 HAU | 7 | 3 | 0 | 100 |
52 | Burmakina et al. (2016) | Congo K ‐49 | DP | 3 | IM | 103 HAU | 8 | 3 | 0 | 100 |
55 | Sanford et al. (2016) | Georgia | DP | 2 | IM | 104 TCID50 | 8 | 0 | 2 | 100 |
56 | Sanford et al. (2016) | Georgia | DP | 5 | IM | 104 TCID50 | 8 | 0 | 5 | 100 |
57 | Gallardo et al. (2018) | Es15/WB‐Tartu14 ASFV | DP | 2 | IM | 10 HAD50 | 78 | 2 | 0 | 100 |
58 | Gallardo et al. (2018) | Es15/WB‐Valga‐6 ASFV | DP | 2 | IM | 10 HAD50 | 78 | 1 | 1 | 100 |
59 | Gallardo et al. (2018) | Es15/WB‐Tartu14 ASFV | DP | 4 | DC | NA | 78 | 2 | 0 | 50 |
60 | Gallardo et al. (2018) | Es15/WB‐Valga‐6 ASFV | DP | 4 | DC | NA | 78 | 2 | 0 | 50 |
61 | Zani et al. (2018) | ASFV from N‐E Estonia | mini‐DP | 12 | ON | 105 HAU | 36 | 1 | 2 | 25 |
62 | Zani et al. (2018) | ASFV from N‐E Estonia | DP | 5 | ON | 105 HAU | 36 | 0 | 0 | 0 |
63 | Zani et al. (2018) | ASFV from N‐E Estonia | WB | 5 | ON | 106.5 HAU | 17 | 2 | 3 | 100 |
64 | Zhao et al. (2019) | DP/HLJ/18 | DP | 1 | IM | NR | 14 | 1 | 0 | 100 |
65 | Zhao et al. (2019) | DP/HLJ/18 | DP | 2 | IM | NR | 14 | 2 | 0 | 100 |
66 | Zhao et al. (2019) | DP/HLJ/18 | DP | 3 | IM | NR | 14 | 3 | 0 | 100 |
67 | Zhao et al. (2019) | DP/HLJ/18 | DP | 3 | IM | NR | 14 | 3 | 0 | 100 |
68 | Zhao et al. (2019) | DP/HLJ/18 | DP | 2 | DC | NR | 14 | 2 | 0 | 100 |
69 | Gallardo et al. (2019) | Lv17/WB/Rie1 (non‐HAD) | DP | 2 | IM | 10 TCID50 | 126 | 0 | 1 | 50 |
70 | Gallardo et al. (2019) | Lv17/WB/Rie1 (non‐HAD) | DP | 4 | DC | NA | 126 | 0 | 3 | 75 |
71 | Gallardo et al. (2019) | Lv17/WB/Zieme3 (HAD) | DP | 1 | IM | 10 TCID50 | 126 | 1 | 100 | |
72 | Gallardo et al. (2019) | Lv17/WB/Zieme3 (HAD) | DP | 1 | DC | NA | 126 | 0 | 1 | 100 |
73 | Cadenas‐Fernandez et al. (2020) | ASFV Arm07 isolate | WB | 2 | IM | 10 HAD50 | 48 | 0 | 2 | 100 |
74 | Walczak et al. (2020) | Pol18_28298_O111 | DP | 8 | IN | 1000 HAU | 32 | 7 | 0 | 87.5 |
75 | Walczak et al. (2020) | Pol18_28298_O111 | DP | 6 | IN | 500 HAU | 24 | 4 | 2 | 100 |
76 | Walczak et al. (2020) | Pol18_28298_O111 | DP | 8 | IN | 5 HAU | 21 | 6 | 2 | 100 |
77 | Borca et al. (2020) | Georgia 2007/1 | DP | 5 | IM | 102 HAD50 | 0 | 5 | 100 | |
78 | Lokhandwala et al. (2019) | ASFV‐Georgia 2007/1 | DP | 5 | IN | 104 TCID50 | 5 | 1 | 2 | 60 |
79 | Lokhandwala et al. (2019) | ASFV‐Georgia 2007/1 | DP | 5 | IN | 104 TCID50 | 5 | 2 | 1 | 60 |
DC: direct contact with infected animals; DP: domestic pig; dpi: days post‐inoculations; HAD: haemadsorption doses; HAU: haemadsorbing units; ID: intradermal; IH: inhalation; IM: intramuscular; IN: intranasal; MTC: Maximum tolerable concentration; NA: not applicable; NR: not reported; O: oral; ON: oronasal; TCID: tissue culture infectious dose; V: vector bite; WB: wild boar.